Monash University
The results from a Phase 1 clinical trial led by the University of California published today in Nature Medicine has found a single dose of the psychedelic substance psilocybin, administered alongside psychological support, is a safe and acceptable treatment for patients with anorexia nervosa and may decrease eating-disorder behaviours in a subset of patients.
Professor Chris Langmead from the Monash Institute of Pharmaceutical Sciences is
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
